Israel-based pharmaceutical company Teva Pharmaceutical and Huntington Study Group (HSG) have reported results of the Phase III trial of SD-809 (deutetrabenazine) tablets to treat chorea associated with Huntington disease (HD).

SD-809 (deutetrabenazine) is an investigational, orally administered small-molecule that inhibits vesicular monoamine 2 transporter (VMAT2).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Phase III trial is a placebo-controlled and randomised First-HD (First Time Use of SD-809 in Huntington Disease) study designed to determine the safety and efficacy of SD-809.

It involved 90 patients afflicted with HD who were randomised 1:1 to be administered with SD-809 or placebo.

Huntington Study Group executive committee member and First-HD trial principal investigator Dr Samuel Frank said: “As a physician who cares for people with HD, it’s gratifying to see positive results from a well-designed, fully enrolled trial.

“Until we find a cure, we aim to bring our patients more treatment options to relieve symptoms.

“Until we find a cure, we aim to bring our patients more treatment options to relieve symptoms.”

“We are grateful to the people who participated in this trial, along with their families and support systems that made their participation possible. Research in the HD community depends on volunteers enrolling in trials.”

HD is a fatal neurodegenerative disease, symptoms of which are uncoordinated and uncontrollable movements such as chorea, cognitive deterioration and behavioural and / or psychological problems.

The symptoms generally tend to occur during middle age, but the disease can also be present in children and the elderly.

The company is also exploring the efficacy of deutetrabenazine in treating tardive dyskinesia and for tics associated with Tourette syndrome.

Image: Microscopic image of neuron with inclusion caused by HD. Photo: courtesy of Leevanjackson via Wikipedia.